How to Use a Johnson & Johnson Org Chart to Identify AI Decision-Makers?
The traditional pharmaceutical sales model, characterized by physical rep visits and linear physician relationships, has hit a functional challenge. At Johnson & Johnson, the strategic pivot toward a "decentralized, BU-led" structure has fundamentally altered how the organization consumes innovation. For marketers, the trigger is no longer about securing a 15-minute slot with a physician, rather it is about navigating a complex web of E-health platforms and AI-driven clinical workflows. If your Go-to-Market (GTM) strategy still treats J&J as a centralized hierarchy rather than a digital-first ecosystem, you are likely hitting the wrong doors. As J&J moves from AI pilots to enterprise-wide implementation, the "Buying Committee" has expanded. It now integrates Heads of Patient Experience and Real-World Evidence (RWE) Leads, creating a multi-layered decision-making process. To succeed, your approach must transition to "Digital Orchestration." Th...